This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know

Company Overview - CG Oncology, Inc. is a biotechnology company focused on innovative therapies for bladder cancer, particularly for high-risk patient populations with unmet medical needs [5] - The company is in the clinical-stage biopharmaceutical sector, primarily generating revenue through clinical development activities and potential future product commercialization [6] - CG Oncology's lead candidate, cretostimogene, aims to provide a differentiated, bladder-sparing treatment option for high-risk non-muscle invasive bladder cancer unresponsive to Bacillus Calmette Guerin (BCG) therapy [7] Financial Performance - As of the latest report, CG Oncology has a market capitalization of $5.5 billion and annual revenue of approximately $4 million, with a net income loss of $160.1 million [4] - The company's shares have increased by 135% over the past year, significantly outperforming the S&P 500's gain of about 15% during the same period [5] - CG Oncology has a strong balance sheet with over $740 million in cash at year-end, which has increased to nearly $900 million recently, providing financial runway into 2029 [9] Recent Developments - Kynam Capital Management reduced its position in CG Oncology by selling 1,059,375 shares for an estimated $43.84 million, resulting in a net position change of $41.50 million [2] - Following the sale, CG Oncology represented 2.51% of Kynam Capital's 13F reportable assets under management (AUM), down from 6.0% in the previous quarter [5] - The company is anticipating significant clinical milestones, including Phase 3 data expected in the first half of 2026, which could influence future performance [8]